胰腺导管腺癌的治疗研究进展
|
摘要
胰腺导管腺癌(PDAC)是一种易发生微转移的恶性肿瘤,其早期缺乏明显症状,但经常侵犯周围正常组织。大部分患者在确诊时已处于晚期,其中局限性和转移性癌的5年生存率仅为23%和5%。如何提高PDAC患者的生存率、优化治疗方案和提高治愈率等是现今急需解决的问题。目前以手术为主的多学科诊治和个体化治疗模式成为研究热点,包括PDAC的发生机制、分期要素治疗、新辅助治疗和术后的监测治疗等。笔者就PDAC的各种治疗方法的研究进展进行综述。
Pancreatic ductal adenocarcinoma(PDAC) is a malignant tumor that is prone to micrometastasis, lacks obvious symptoms in early stage, but often invades the surrounding healthy tissues. The majority of patients are found to be at an advanced stage at the time of diagnosis, the 5-year survival rates of those with localized cancer and metastatic cancer are only 23% and 5%, respectively. Therefore, how to improve the survival rate of PDAC patients, optimize the therapeutic schedule and increase the cure rate are currently urgent issues. At present, operation-based multidisciplinary treatment and individualized treatment mode have become the research focuses, which include the pathogenetic mechanism, staged treatment strategy, neoadjuvant therapy and postoperative monitoring of PDAC. The authors address the research progress of various treatment methods for PDAC.
Pancreatic ductal adenocarcinoma(PDAC) is a malignant tumor that is prone to micrometastasis, lacks obvious symptoms in early stage, but often invades the surrounding healthy tissues. The majority of patients are found to be at an advanced stage at the time of diagnosis, the 5-year survival rates of those with localized cancer and metastatic cancer are only 23% and 5%, respectively. Therefore, how to improve the survival rate of PDAC patients, optimize the therapeutic schedule and increase the cure rate are currently urgent issues. At present, operation-based multidisciplinary treatment and individualized treatment mode have become the research focuses, which include the pathogenetic mechanism, staged treatment strategy, neoadjuvant therapy and postoperative monitoring of PDAC. The authors address the research progress of various treatment methods for PDAC.
引文
[1]Du L, Wang-Gillam A. Trends in Neoadjuvant Approaches in Pancreatic Cancer[J]. J Natl Compr Canc Netw, 2017, 15(8):1070-1077. doi:10.6004/jnccn.2017.0134.
[2]Wolff RA, Wang-Gillam A, Alvarez H, et al. Dynamic changes during the treatment of pancreatic cancer[J]. Oncotarget, 2018,9(19):14764-14790. doi:10.18632/oncotarget.24483.
[3]Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma:Current and Evolving Therapies[J]. Int J Mol Sci,2017, 18(7). pii:E1338. doi:10.3390/ijms 18071338.
[4]Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma[J]. Int J Mol Sci. 2017,18(3). pii:E667. doi:10.3390/ijms18030667.
[5]黄耿文,宁彩虹,申鼎成,等.《日本胰腺协会胰腺癌临床实践指南(2016)》解读[J].中国普通外科杂志,2017, 26(9):1093-1096.doi:10.3978/j.issn. 1005-6947.2017.09.003.Huang GW, Ning CH, Shen DC, et al. Interpretation of Clinical Practice Guidelines for Pancreatic Cancer 2016 from the Japan Pancreas Society[J]. Chinese Journal of General Surgery, 2017,26(9):1093-1096. doi:10.3978/j.issn. 1005-6947.2017.09.003.
[6]祁冰,高建平,尚东.《2017年国际胰腺病学会共识:可能切除的胰腺导管腺癌的定义和标准》摘译[J].临床肝胆病杂志,2018,34(3):502-507. doi:10.3969/j.issn.1001-5256.2018.03.010.Qi B, Gao JP, Shang D. An excerpt of international consensus on definition and criteria of borderline resectable pancreatic ductal adenocarci-noma 2017[J]. Chinese Journal of Clinical Hepatology,2018, 34(3):502-507. doi:10.3969/j.issn.1001-5256.2018.03.010.
[7]郑苏丽,张太平.ASCO、NCCN临床实践指南关于可切除及可能切除胰腺癌诊治的共识与争议[J].中国普通外科杂志,2017,26(9):1085-1088. doi:10.3978/j.issn. 1005-6947.2017.09.001.Zheng SL, Zhang TP. Consensus and controversy about resectable and possibly resectable pancreatic cancer between ASCO and NCCN clinical practice guideline[J]. Chinese Journal of General Surgery, 2017, 26(9):1085-1088. doi:10.3978/j.issn. 1005-6947.2017.09.001.
[8]Saka B, Balci S, Basturk O, et al. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol(7th Edition)Inapplicable and Insignificant:A Size-Based Staging System(pTl:≤2, pT2:>2-≤4, pT3:>4 cm)is More Valid and Clinically Relevant[J]. Ann Surg Oncol, 2016, 23(6):2010-2018.doi:10.1245/s 10434-016-5093-7.
[9]Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer(8th Edition)Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma[J]. Ann Surg, 2017, 265(1):185-191. doi:10.1097/SLA.0000000000001763.
[10]Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma:number of positive nodes allows to distinguish several N categories[J]. Ann Surg, 2015, 261(5):961-969. doi:10.1097/SL A.0000000000000814.
[11]Hartwig W,Vollmer CM,Fingerhut A.et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma:definition and consensus of the International Study Group for Pancreatic Surgery(ISGPS)[J]. Surgery, 2014, 156(1):1-14. doi:10.1016/j.surg.2014.02.009.
[12]Hammel P,Huguet F, van Laethem JL,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib:The LAP07 Randomized Clinical Trial[J]. JAMA, 2016, 315(17):1844-1853. doi:10.1001/jama.2016.4324.
[13]Reni M,Cereda S,Mazza E,et al. PEFG(cisplatin,epirubicin,5-fluorouracil,gemcitabine)regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy[J]. Am J Clin Oncol, 2008,31(2):145-150. doi:10.1097/COC.0b013e31814688f7.
[14]赵华,董晓丽.吉西他滨联合紫杉醇对比S-1联合吉西他滨在治疗胰腺癌的疗效对比[J].中外医疗,2017, 36(18):123-124.doi:10.16662/j.cnki.1674-0742.2017.18.123.Zhao H, Dong XL. Comparison of Curative Effect of Gemcitabine and Paclitaxel and S-1 and Gemcitabine in Treatment of Carcinoma of Pancreas[J]. China Foreign Medical Treatment, 2017,36(18):123-124. doi:10.16662/j.cnki.1674-0742.2017.18.123.
[15]寇炜,郭代红,王伟兰,等.白蛋白结合型紫杉醇相关药品不良反应的自动监测研究[J].药物流行病学杂志,2017, 26(2):111-114.Kou W, Guo DH, Wang WL, et al. Study on Adverse Drug Reactions Related to Albumin-bound Paclitaxel by Automatic Surveillance[J]. Chinese Journal of Pharmacoepidemiology, 2017,26(2):111-114.
[16]Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18):1691-1703. doi:10.1056/NEJMoa1304369.
[17]Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer:long-term survival from a phase III trial[J]. J. Natl. Cancer Inst, 2015, 107(2). pii:dju413. doi:10.1093/jnci/dju413.
[18]ThotaR, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma:a review[J]. Oncology(Williston Park), 2014,28(1):70-74.
[19]Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al.Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer:Results from the PRODIGE 4/ACCORD 11 randomized trial[J]. J Clin Oncol, 2013,31(1):23-29. doi:10.1200/JC0.2012.44.4869.
[20]Sirohi B, Dawood S, Rastogi S, et al. Treatment of patients with metastatic pancreatic cancer:Experience from a tertiary Indiancancer center[J]. Indian J Cancer, 2015, 52(3):449-452. doi:10.4103/0019-509X. 176732.
[21]Toomey P, Hernandez J, Morton C, et al, Resection of portovenous structures to obtain microscopically negative margins during pancreaticoduodentomy for pancreatic adenocarcinoma is worthwhile[J]. Am Surg, 2009, 75(9):804-810.
[22]Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma[J]. Expert Rev Anticancer Ther,2018, 18(1):51-62. doi:10.1080/14737140.2018.1403319.
[23]杨永超,李宜雄.胰腺癌外科治疗的历史和现状[J].中国普通外科杂志,2018,27(3):269-283. doi:10.3978/j.issn. 1005-6947.2018.03.002.Yang YC, Li YX. The surgical treatment of pancreatic cancer:history and present state[J]. Chinese Journal of General Surgery,2018, 27(3):269-283.doi:10.3978/j.issn. 1005-6947.2018.03.002.
[24]Loosen SH, Neumann UP, Trautwein C, et al. Current and future biomarkers for pancreatic adenocarcinoma[J]. Tumour Biol, 2017,39(6):1010428317692231. doi:10.1177/1010428317692231.
[25]Yang A, O'Reilly EM. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma[J]. Expert Rev Gastroenterol Hepatol,2015, 9(5):585-601. doi:10.1586/17474124.2015.1012496.
[26]Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer:A Propensity Score Matched Analysis[J]. J Clin Oncol, 2017, 35(5):515-522. doi:10.1200/JC0.2016.68.5081.
[27]Epelboym I,DiNorcia J,Winner M,et al. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy:shifting the survival curve for patients with locally advanced pancreatic cancer[J]. World J Surg, 2014, 38(5):1184-1195. doi:10.1007/s00268-013-2384-z.
[28]Sano T, Takano K, Chiba N,et al. The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer[J]. Gan To Kagaku Ryoho, 2015, 42(12):1488-1490.
[29]蒋奎荣,涂敏,苗毅.胰腺癌新辅助治疗的有效性与安全性[J].中国实用外科杂志,2017, 37(7):772-773.Jiang KR, Tu M, Miao Y. Efficacy and safety of neoadjuvant therapy of pancreatic cancer[J]. Chinese Journal of Practical Surgery, 2017,37(7):772-773.
[30]Petrelli F, Coinu A, Borgonovo K, et, al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer:a meta-analytical review of published studies[J]. Pancreas, 2015, 44(4):515-521. doi:10.1097/MPA.0000000000000314.
[31]Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in respectable pancreatic adenocarcinoma[J]. Cancer, 2011, 117(10):2044-2049. doi:10.1002/cncr.25763.
[32]Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer:A Single-Center Prospective,Randomized, Controlled Trial Which Failed to Achieve Accrual Targets[J]. J Gastrointest Surg, 2015, 19(10):1802-1812. doi:10.1007/s11605-015-2890-4.
[33]Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer:results of the first prospective randomized phaseⅡtrial[J]. Strahlenther Onkol, 2015, 191(1):7-16. doi:10.1007/s00066-014-0737-7.
[34]Fitzgerald TL, Lertpiriyapong K, Cocco L, et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells[J]. Adv Biol Regul, 2015,59:65-81. doi:10.1016/j.jbior.2015.06.003.
[35]粱贇,姜翀弋,王巍.胰腺癌的靶向治疗[J].外科理论与实践,2017, 22(1):84-88.Liang Y, Jiang CG, Wang W. Target therapy of pancreatic cancer[J].Journal of Surgery Concepts&Practice,2017, 22(1):84-88.
[36]Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007,25(15):1960-1966. doi:10.1200/JC0.2006.07.9525.
[37]Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine[J].Clin Cancer Res, 2006, 12(16):4925-4932. doi:10.1158/1078-0432.CCR-06-0544.
[38]McCaffery I, Tudor Y, Deng H, et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor[J].Clin Cancer Res, 2013, 19(15):4282-4289. doi:10.1 158/1078-0432.CCR-12-1840.
[39]Fuchs CS, Azevedo S, Okusak T, et al. A phase 3 randomized,double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas:the GAMMA trial[J]. Ann Oncol,2015, 26(5):921-927. doi:10.1093/annonc/mdv027.
[40]Xu Z, Pothula SP, Wilson JS, et al. Pancreatic cancer and its stroma:A conspiracy theory[J]. World J Gastroenterol, 2014, 20(32):11216-11229. doi:10.3748/wjg.v20.i32.11216.
[41]邢荣春,秦周萍.胰腺导管腺癌肿瘤微环境的研究进展[J].中国普通外科杂志,2017,26(9):1202-1206.doi:10.3978/j.issn.1005-6947.2017.09.019.Xing RC, Qin ZP. Research progress of tumor microenvironment in pancreatic ductal adenocarcinoma[J]. Chinese Journalof General Surgery, 2017, 26(9):1202-1206. doi:10.3978/j.issn. 1005-6947.2017.09.019.
[42]Neesse A, Krug S, Gress TM, et al. Emerging concepts in pancreatic cancer medicine:Targeting the tumor stroma[J]. OncoTargets Ther,2013, 7:33-43. doi:10.2147/OTT.S38111.
[43]宋沂林,刘泽杰,杨静,等.胰腺癌免疫治疗进展[J].现代肿瘤医学,2017, 25(10):1651-1655. doi:10.3969/j.issn.1672-4992.2017.10.036.Song QL, Liu ZJ, Yang J, et al. Research progress of immunotherapy for pancreatic carcinoma[J]. Journal of Modern Oncology, 2017,25(10):1651-1655. doi:10.3969/j.issn. 1672-4992.2017.10.036.
[44]Zhang Y, Velez-Delgado A, Mathew E, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer[J]. Gut, 2017, 66(1):124-136. doi:10.1136/gutjnl-2016-312078.
[45]Vonderheide RH, Bajor DL, Winograd R, et al. CD40immunotherapy for pancreatic cancer[J]. Cancer Immunol.Immunother, 2013, 62(5):949-954. doi:10.1007/s00262-013-1427-5.
[46]Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans[J]. Science, 2011, 331(6024):1612-1616. doi:10.1126/science. 1198443.
[47]Li Y, Sarkar FH. MicroRNA targeted therapeutic approach for pancreatic cancer[J]. Int J Biol Sci, 2016, 12(3):326-337. doi:10.7150/ijbs.15017.
[48]Papaconstantinou 1G, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance[J]. Pancreas, 2013, 42(1):67-71. doi:10.1097/MPA.0b013e3182592ba7.
[49]Kadera BE, Li L, Toste PA, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis[J]. PLoS One, 2013, 8(8):e71978. doi:10.1371/journal.pone.0071978..
[50]Ali S, Banerjee S, Logna F, et al. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer[J]. J Cell Physiol, 2012, 227(10):3373-3380. doi:10.1002/jcp.24036.
[51]Farrell JJ, Toste P, Wu N, et al. Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer[J]. Am J Gastroenterol, 2013, 108(8):1352-1359. doi:10.1038/ajg.2013.167.
[52]Liu C, Cheng H, Shi S, et al. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3[J]. Curr Mol Med,2013, 13(4):467-478.
[2]Wolff RA, Wang-Gillam A, Alvarez H, et al. Dynamic changes during the treatment of pancreatic cancer[J]. Oncotarget, 2018,9(19):14764-14790. doi:10.18632/oncotarget.24483.
[3]Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma:Current and Evolving Therapies[J]. Int J Mol Sci,2017, 18(7). pii:E1338. doi:10.3390/ijms 18071338.
[4]Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma[J]. Int J Mol Sci. 2017,18(3). pii:E667. doi:10.3390/ijms18030667.
[5]黄耿文,宁彩虹,申鼎成,等.《日本胰腺协会胰腺癌临床实践指南(2016)》解读[J].中国普通外科杂志,2017, 26(9):1093-1096.doi:10.3978/j.issn. 1005-6947.2017.09.003.Huang GW, Ning CH, Shen DC, et al. Interpretation of Clinical Practice Guidelines for Pancreatic Cancer 2016 from the Japan Pancreas Society[J]. Chinese Journal of General Surgery, 2017,26(9):1093-1096. doi:10.3978/j.issn. 1005-6947.2017.09.003.
[6]祁冰,高建平,尚东.《2017年国际胰腺病学会共识:可能切除的胰腺导管腺癌的定义和标准》摘译[J].临床肝胆病杂志,2018,34(3):502-507. doi:10.3969/j.issn.1001-5256.2018.03.010.Qi B, Gao JP, Shang D. An excerpt of international consensus on definition and criteria of borderline resectable pancreatic ductal adenocarci-noma 2017[J]. Chinese Journal of Clinical Hepatology,2018, 34(3):502-507. doi:10.3969/j.issn.1001-5256.2018.03.010.
[7]郑苏丽,张太平.ASCO、NCCN临床实践指南关于可切除及可能切除胰腺癌诊治的共识与争议[J].中国普通外科杂志,2017,26(9):1085-1088. doi:10.3978/j.issn. 1005-6947.2017.09.001.Zheng SL, Zhang TP. Consensus and controversy about resectable and possibly resectable pancreatic cancer between ASCO and NCCN clinical practice guideline[J]. Chinese Journal of General Surgery, 2017, 26(9):1085-1088. doi:10.3978/j.issn. 1005-6947.2017.09.001.
[8]Saka B, Balci S, Basturk O, et al. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol(7th Edition)Inapplicable and Insignificant:A Size-Based Staging System(pTl:≤2, pT2:>2-≤4, pT3:>4 cm)is More Valid and Clinically Relevant[J]. Ann Surg Oncol, 2016, 23(6):2010-2018.doi:10.1245/s 10434-016-5093-7.
[9]Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional Validation Study of the American Joint Commission on Cancer(8th Edition)Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma[J]. Ann Surg, 2017, 265(1):185-191. doi:10.1097/SLA.0000000000001763.
[10]Strobel O, Hinz U, Gluth A, et al. Pancreatic adenocarcinoma:number of positive nodes allows to distinguish several N categories[J]. Ann Surg, 2015, 261(5):961-969. doi:10.1097/SL A.0000000000000814.
[11]Hartwig W,Vollmer CM,Fingerhut A.et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma:definition and consensus of the International Study Group for Pancreatic Surgery(ISGPS)[J]. Surgery, 2014, 156(1):1-14. doi:10.1016/j.surg.2014.02.009.
[12]Hammel P,Huguet F, van Laethem JL,et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib:The LAP07 Randomized Clinical Trial[J]. JAMA, 2016, 315(17):1844-1853. doi:10.1001/jama.2016.4324.
[13]Reni M,Cereda S,Mazza E,et al. PEFG(cisplatin,epirubicin,5-fluorouracil,gemcitabine)regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy[J]. Am J Clin Oncol, 2008,31(2):145-150. doi:10.1097/COC.0b013e31814688f7.
[14]赵华,董晓丽.吉西他滨联合紫杉醇对比S-1联合吉西他滨在治疗胰腺癌的疗效对比[J].中外医疗,2017, 36(18):123-124.doi:10.16662/j.cnki.1674-0742.2017.18.123.Zhao H, Dong XL. Comparison of Curative Effect of Gemcitabine and Paclitaxel and S-1 and Gemcitabine in Treatment of Carcinoma of Pancreas[J]. China Foreign Medical Treatment, 2017,36(18):123-124. doi:10.16662/j.cnki.1674-0742.2017.18.123.
[15]寇炜,郭代红,王伟兰,等.白蛋白结合型紫杉醇相关药品不良反应的自动监测研究[J].药物流行病学杂志,2017, 26(2):111-114.Kou W, Guo DH, Wang WL, et al. Study on Adverse Drug Reactions Related to Albumin-bound Paclitaxel by Automatic Surveillance[J]. Chinese Journal of Pharmacoepidemiology, 2017,26(2):111-114.
[16]Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18):1691-1703. doi:10.1056/NEJMoa1304369.
[17]Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer:long-term survival from a phase III trial[J]. J. Natl. Cancer Inst, 2015, 107(2). pii:dju413. doi:10.1093/jnci/dju413.
[18]ThotaR, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma:a review[J]. Oncology(Williston Park), 2014,28(1):70-74.
[19]Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al.Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer:Results from the PRODIGE 4/ACCORD 11 randomized trial[J]. J Clin Oncol, 2013,31(1):23-29. doi:10.1200/JC0.2012.44.4869.
[20]Sirohi B, Dawood S, Rastogi S, et al. Treatment of patients with metastatic pancreatic cancer:Experience from a tertiary Indiancancer center[J]. Indian J Cancer, 2015, 52(3):449-452. doi:10.4103/0019-509X. 176732.
[21]Toomey P, Hernandez J, Morton C, et al, Resection of portovenous structures to obtain microscopically negative margins during pancreaticoduodentomy for pancreatic adenocarcinoma is worthwhile[J]. Am Surg, 2009, 75(9):804-810.
[22]Karakas Y, Lacin S, Yalcin S. Recent advances in the management of pancreatic adenocarcinoma[J]. Expert Rev Anticancer Ther,2018, 18(1):51-62. doi:10.1080/14737140.2018.1403319.
[23]杨永超,李宜雄.胰腺癌外科治疗的历史和现状[J].中国普通外科杂志,2018,27(3):269-283. doi:10.3978/j.issn. 1005-6947.2018.03.002.Yang YC, Li YX. The surgical treatment of pancreatic cancer:history and present state[J]. Chinese Journal of General Surgery,2018, 27(3):269-283.doi:10.3978/j.issn. 1005-6947.2018.03.002.
[24]Loosen SH, Neumann UP, Trautwein C, et al. Current and future biomarkers for pancreatic adenocarcinoma[J]. Tumour Biol, 2017,39(6):1010428317692231. doi:10.1177/1010428317692231.
[25]Yang A, O'Reilly EM. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma[J]. Expert Rev Gastroenterol Hepatol,2015, 9(5):585-601. doi:10.1586/17474124.2015.1012496.
[26]Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer:A Propensity Score Matched Analysis[J]. J Clin Oncol, 2017, 35(5):515-522. doi:10.1200/JC0.2016.68.5081.
[27]Epelboym I,DiNorcia J,Winner M,et al. Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy:shifting the survival curve for patients with locally advanced pancreatic cancer[J]. World J Surg, 2014, 38(5):1184-1195. doi:10.1007/s00268-013-2384-z.
[28]Sano T, Takano K, Chiba N,et al. The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer[J]. Gan To Kagaku Ryoho, 2015, 42(12):1488-1490.
[29]蒋奎荣,涂敏,苗毅.胰腺癌新辅助治疗的有效性与安全性[J].中国实用外科杂志,2017, 37(7):772-773.Jiang KR, Tu M, Miao Y. Efficacy and safety of neoadjuvant therapy of pancreatic cancer[J]. Chinese Journal of Practical Surgery, 2017,37(7):772-773.
[30]Petrelli F, Coinu A, Borgonovo K, et, al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer:a meta-analytical review of published studies[J]. Pancreas, 2015, 44(4):515-521. doi:10.1097/MPA.0000000000000314.
[31]Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in respectable pancreatic adenocarcinoma[J]. Cancer, 2011, 117(10):2044-2049. doi:10.1002/cncr.25763.
[32]Casadei R, Di Marco M, Ricci C, et al. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer:A Single-Center Prospective,Randomized, Controlled Trial Which Failed to Achieve Accrual Targets[J]. J Gastrointest Surg, 2015, 19(10):1802-1812. doi:10.1007/s11605-015-2890-4.
[33]Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer:results of the first prospective randomized phaseⅡtrial[J]. Strahlenther Onkol, 2015, 191(1):7-16. doi:10.1007/s00066-014-0737-7.
[34]Fitzgerald TL, Lertpiriyapong K, Cocco L, et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells[J]. Adv Biol Regul, 2015,59:65-81. doi:10.1016/j.jbior.2015.06.003.
[35]粱贇,姜翀弋,王巍.胰腺癌的靶向治疗[J].外科理论与实践,2017, 22(1):84-88.Liang Y, Jiang CG, Wang W. Target therapy of pancreatic cancer[J].Journal of Surgery Concepts&Practice,2017, 22(1):84-88.
[36]Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007,25(15):1960-1966. doi:10.1200/JC0.2006.07.9525.
[37]Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine[J].Clin Cancer Res, 2006, 12(16):4925-4932. doi:10.1158/1078-0432.CCR-06-0544.
[38]McCaffery I, Tudor Y, Deng H, et al. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor[J].Clin Cancer Res, 2013, 19(15):4282-4289. doi:10.1 158/1078-0432.CCR-12-1840.
[39]Fuchs CS, Azevedo S, Okusak T, et al. A phase 3 randomized,double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas:the GAMMA trial[J]. Ann Oncol,2015, 26(5):921-927. doi:10.1093/annonc/mdv027.
[40]Xu Z, Pothula SP, Wilson JS, et al. Pancreatic cancer and its stroma:A conspiracy theory[J]. World J Gastroenterol, 2014, 20(32):11216-11229. doi:10.3748/wjg.v20.i32.11216.
[41]邢荣春,秦周萍.胰腺导管腺癌肿瘤微环境的研究进展[J].中国普通外科杂志,2017,26(9):1202-1206.doi:10.3978/j.issn.1005-6947.2017.09.019.Xing RC, Qin ZP. Research progress of tumor microenvironment in pancreatic ductal adenocarcinoma[J]. Chinese Journalof General Surgery, 2017, 26(9):1202-1206. doi:10.3978/j.issn. 1005-6947.2017.09.019.
[42]Neesse A, Krug S, Gress TM, et al. Emerging concepts in pancreatic cancer medicine:Targeting the tumor stroma[J]. OncoTargets Ther,2013, 7:33-43. doi:10.2147/OTT.S38111.
[43]宋沂林,刘泽杰,杨静,等.胰腺癌免疫治疗进展[J].现代肿瘤医学,2017, 25(10):1651-1655. doi:10.3969/j.issn.1672-4992.2017.10.036.Song QL, Liu ZJ, Yang J, et al. Research progress of immunotherapy for pancreatic carcinoma[J]. Journal of Modern Oncology, 2017,25(10):1651-1655. doi:10.3969/j.issn. 1672-4992.2017.10.036.
[44]Zhang Y, Velez-Delgado A, Mathew E, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer[J]. Gut, 2017, 66(1):124-136. doi:10.1136/gutjnl-2016-312078.
[45]Vonderheide RH, Bajor DL, Winograd R, et al. CD40immunotherapy for pancreatic cancer[J]. Cancer Immunol.Immunother, 2013, 62(5):949-954. doi:10.1007/s00262-013-1427-5.
[46]Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans[J]. Science, 2011, 331(6024):1612-1616. doi:10.1126/science. 1198443.
[47]Li Y, Sarkar FH. MicroRNA targeted therapeutic approach for pancreatic cancer[J]. Int J Biol Sci, 2016, 12(3):326-337. doi:10.7150/ijbs.15017.
[48]Papaconstantinou 1G, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance[J]. Pancreas, 2013, 42(1):67-71. doi:10.1097/MPA.0b013e3182592ba7.
[49]Kadera BE, Li L, Toste PA, et al. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis[J]. PLoS One, 2013, 8(8):e71978. doi:10.1371/journal.pone.0071978..
[50]Ali S, Banerjee S, Logna F, et al. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer[J]. J Cell Physiol, 2012, 227(10):3373-3380. doi:10.1002/jcp.24036.
[51]Farrell JJ, Toste P, Wu N, et al. Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer[J]. Am J Gastroenterol, 2013, 108(8):1352-1359. doi:10.1038/ajg.2013.167.
[52]Liu C, Cheng H, Shi S, et al. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3[J]. Curr Mol Med,2013, 13(4):467-478.